Cargando…
Machine Learning for Predicting Hyperglycemic Cases Induced by PD-1/PD-L1 Inhibitors
OBJECTIVE: Immune checkpoint inhibitors, such as programmed death-1/ligand-1 (PD-1/L1), exhibited autoimmune-like disorders, and hyperglycemia was on the top of grade 3 or higher immune-related adverse events. Machine learning is a model from past data for future data prediction. From post-marketing...
Autores principales: | Yang, Jincheng, Li, Ning, Lin, Weilong, Shi, Liming, Deng, Ming, Tong, Qin, Yang, Wenjing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417778/ https://www.ncbi.nlm.nih.gov/pubmed/36032541 http://dx.doi.org/10.1155/2022/6278854 |
Ejemplares similares
-
PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019) -
PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study
por: Chen, Mifen, et al.
Publicado: (2023) -
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018) -
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017) -
The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)